Immediate Impact
36 standout
Citing Papers
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
2025 Standout
Insights into IL-6/JAK/STAT3 signaling in the tumor microenvironment: Implications for cancer therapy
2025 Standout
Works of Christopher Wolf being referenced
Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer
2012
A first-in-human phase I clinical trial of CXR1002 in patients (pts) with advanced cancer.
2011
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Christopher Wolf | 122 | 5 | 17 | 27 | 7 | 171 | |
| Antonella Racano | 158 | 6 | 27 | 45 | 5 | 265 | |
| Tomás Echeverría | 51 | 6 | 23 | 21 | 7 | 196 | |
| E. Boldó | 170 | 8 | 36 | 49 | 11 | 232 | |
| JI Weitz | 82 | 7 | 25 | 40 | 7 | 204 | |
| John McDonald | 85 | 26 | 52 | 31 | 9 | 295 | |
| Miki Scaravaglio | 86 | 16 | 43 | 62 | 10 | 158 | |
| Laura Sala | 117 | 13 | 31 | 117 | 10 | 217 | |
| Roberto Maria Romano | 86 | 14 | 41 | 44 | 9 | 222 | |
| Nobuaki Nishimata | 117 | 9 | 24 | 24 | 11 | 170 | |
| Gerald L. MacKean | 113 | 1 | 9 | 11 | 8 | 263 |
All Works
Loading papers...